How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma
Cells · 2026
DOI: 10.3390/cells15110986 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Ivana Persico und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cancer Genetics, Institute of Genetics and Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy. Hauptthemen laut MEDLINE: Melanoma, Tumor Microenvironment, Immune Checkpoint Inhibitors, mRNA Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research.
Abstract (Originalsprache)
Messenger RNA (mRNA) vaccines are emerging as promising tools capable of reshaping how cancer interacts with the immune system and responds to immunotherapy. These vaccines not only act as platforms for antigen delivery but can also influence the tumor microenvironment (TME), fostering a shift from immunologically “cold’’ conditions toward “hotter’’ and treatment-responsive states. In melanoma, this capability has been found to enhance the efficacy of the immune checkpoint inhibitors (ICIs), as mRNA-based priming can provide the robust antitumor activation needed for more effective checkpoint blockade. Early clinical studies with personalized or off-the-shelf vaccines showed benefits in patients with high-risk resected melanoma or refractory to PD-1 inhibition. Combining mRNA vaccines with ICIs, along with other immunomodulatory strategies, may be helpful to overcome resistance arising from the TME and achieve more durable clinical benefits. Besides these advances, computational and in silico modeling are providing new insights into how mRNA vaccines modulate the TME, helping to identify factors such as antigen-presenting cell (APC) density, CD8+ T-cell infiltration, and macrophage polarization that may predict treatment success and guide personalized strategies. Together, these developments indicate that combining mRNA vaccination with ICIs, supported by computational tools, may improve clinical outcomes in melanoma and, potentially, in selected tumor types with favorable immunological features, although important biological constraints limit direct extrapolation to less immunogenic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Cancer Genetics, Institute of Genetics and Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy.
- Istituto Nazionale Tumori (INT), Fondazione "Giovanni Pascale", 80040 Naples, Italy.
- Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli Studi di Napoli "Federico II", 80040 Naples, Italy.
- Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, 07100 Sassari, Italy.
ORCID-Profile: Laura Frogheri, Antonella Manca, Domenico Mallardo, Giuseppe Palmieri
Förderung
- Italian Association for Cancer Research
Zitieren
APA
Persico, I., Doro, M. G., Frogheri, L., Sini, M. C., Maestrale, G. B., Manca, A., Mallardo, D., Ascierto, P. A., & Palmieri, G. (2026). How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma. Cells. https://doi.org/10.3390/cells15110986
Vancouver
Persico I, Doro MG, Frogheri L, Sini MC, Maestrale GB, Manca A, et al. How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma. Cells. 2026. doi:10.3390/cells15110986
BibTeX
@article{Persico2026,
author = {Persico, Ivana and Doro, Maria Grazia and Frogheri, Laura and Sini, Maria Cristina and Maestrale, Giovanni Battista and Manca, Antonella and Mallardo, Domenico and Ascierto, Paolo Antonio and Palmieri, Giuseppe},
title = {How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15110986}
}
EUVIMED